(290) Precision-Activated Masked Antibodies Reduce Immune Toxicities in Checkpoint blockade Cancer Therapy
Introduction: The use of monoclonal antibodies that target immune checkpoint pathways has significantly advanced cancer immunotherapy, showing long-lasting responses in certain patients. However, these agents can induce immune-related adverse events (irAEs), which range from moderate to severe and may require discontinuation of treatment. In this study, we explore the potential of tumor microenvironment (TME)-responsive polymer masks to selectively shield checkpoint-blocking antibodies. This approach aims to reduce systemic exposure and minimize irAEs, while maintaining targeted delivery to tumors.
Learning Objectives:
Understand the prevalence of adverse events in cancer immunotherapy.
Recognize the importance of minimizing systemic exposure to antibodies to reduce off-target effects.
Develop a reliable strategy for site-specific antibody delivery.
